Status:
RECRUITING
Antisecretory Factor In Severe Traumatic Brain Injury
Lead Sponsor:
Peter Siesjö
Collaborating Sponsors:
Skane University Hospital
Lantmannen Medical AB
Conditions:
Traumatic Brain Injury
Eligibility:
All Genders
10-70 years
Phase:
PHASE2
Brief Summary
This study evaluates the addition of Salovum, an egg yolk powder enriched for antisecretory factor, to standard care of participants with severe traumatic brain injury. Half of the participants will b...
Detailed Description
Cerebral edema accounts for an essential part of the morbidity and mortality in severe traumatic brain injury but can also arise in other cerebral pathologies such as infectious and ischemic condition...
Eligibility Criteria
Inclusion
- Severe traumatic brain injury, Glasgow Outcome Scale (GCS) \<9 at admission to NICU.
- Clinical indication for insertion of intracranial pressure monitor, intracerebral oxygen pressure monitor and microdialysis catheter.
- Consultation with relatives or consent from guardians.
Exclusion
- Known egg yolk allergy.
- Unilateral or bilateral fixed and dilated pupil after initial operative intervention.
Key Trial Info
Start Date :
March 10 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2025
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04117672
Start Date
March 10 2020
End Date
June 30 2025
Last Update
October 1 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Skane University Hopsital
Lund, Sweden, 22185